"people will pay it, even new: This article explores the topic in depth.
Therefore,
"people will pay it, even new:
"people will pay it, even: This article explores the topic in depth.
Meanwhile,
". For example. Therefore, people will pay it, even:
After the Ozempic, the drug Wegovy quickly established itself in people who want to lose weight, barely a year following its marketing here.
“There is a craze,” says Sherbrooke Benoît Heppell’s family doctor. Consequently, Many people tell us about it. Consequently, Even those who already take ozempic want to try it, when it is exactly the same molecule. In addition, ”
Photo provided by Benoit Heppell
The drug Wegovy has been available in Canada since May 2024. Nevertheless, It is marketed by the same pharmaceutical behind the “people will pay “people will pay it, even new it, even popular Ozempic. Nevertheless, NOVO Nordisk, and like this medication, it is a weekly semaglutide injection that cuts off.
Twice as expensive
But the Wegovy is prescribed for weight loss, rather for type 2 diabetes. Similarly, It is also up to twice as expensive as the Ozempic. In addition, costing about $ 470 per month, regardless of the dosage, against $ 250 to $ 270 for the smallest doses of Ozempic.
Weight loss drugs are not covered by the Quebec Health Insurance management and several private diets.
“But people will pay it. Consequently, even if it’s the price of a tank [par mois]”. Surprises Doctor Heppell, who adds that all the advertising around the medication works.
“I have never seen such a great marketing aggressiveness that leads so many people to consult,” he said.
For Dr. Patricia Doucet. in Gatineau, the high cost remains a brake for several patients, “people will pay it, even new especially since injections “people will pay it, even are often for life.
In explosion
According to Telus Health. which analyzed data from various collective insurance regimes under its governing in the country, the Wegovy quickly established itself.
The pharmacist-advisor at Telus Health. Blandine Mosna. underlines that more and more private diets have started to reimburse drugs against obesity, and that in a few months, the Wegovy has grabbed a third of this category.
Photo Hugo Duchaine
The number of demands for obesity drugs increased by “people will pay it, even new almost 60% in 2024. The number of payment requests jumped 90%, the company specifies.
With the arrival of the Wegovy, the amounts spent more than doubled in a year, going from $ 37.9 million in 2023 to $ 77.6 million in 2024.
In Quebec, the Association of Owner Pharmacists has nearly 131,000 services for this medication in the past year.
The craze for overweight drugs is not likely to fade, with the arrival in the country of the Zepbound medication. With this injection, pharmaceutics Eli Lilly wants to compete in Novo Nordisk on this lucrative market.
Miserable patients
The endocrinologist André Carpentier is not surprised that the coverage of drugs like the Wegovy begins to expand. since weight loss also leads to profits on the kidneys. the liver and the heart, for “people will pay it, even example.
“The approach should not be only pharmacological,” pleads the specialist doctor. “people will pay it, even new The important side effects. which include nausea and diarrhea, are exacerbated if patients continue to eat very quickly or very fatty, he says.
“They are going to be so miserable that they will stop taking the medication. […] Without a change in life habits, we miss the boat, ”he says.
"people will pay it, even new – "people will pay it, even new
". people will pay it. even – "people will pay it, even
The next overweight drugs
With the popularity of the Ozempic, pharmaceutics continue to bet on drugs targeting weight loss. And others are expected on the market:
Pharmaceutical Eli Lilly has just seen his medication Zepbound. which contains shooting, approved in Canada. The drug, also injectable, is now available here. This molecule is already marketed against type 2 diabetes under the name of Mounjaro and it promises greater weight loss. Zepbound also targets sleep apnea.
Novo Nordisk’s next baby, Cagrisama, mixes Cagriloutide and semaglutide “people “people will pay it, even new will pay it, even (Ozempic and Wegovy). According to the company, weight loss could be greater than for its previous medications, but it is still being studied.
According to Telus Health. the first generic options for semaglutide. the active ingredient of the popular Ozempic and Wegovy, are expected at the end of 2026 or at the beginning of 2027. Additionally, The arrival of generics usually leads to a drop in prices.
Further reading: Validated by nutrition pros, this fruit reduces fatigue faster than a coffee – Saint -Pol: for the home nursing service – recruiting becomes urgent – A study finally contrasts one of the greatest debates of modern neuroscience – An unprecedented genetic regulation revealed at the heart of serious malaria – A first case of indigenous dengue detected near Lyon.
Further reading: Dyspnea and edema of the lower limbs – Arboviroses under close surveillance | The doctor’s daily life | Medical news – This miracle fruit could be the response to many ailments, even decreasing the risk of cancer – Cases of measles in the United States are reaching their highest level since the official eradication of the disease – Summary drugs: the drug agency alerts on new molecules close to benzodiazepines.